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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S150Results: Leg extensionmuscle power increased 29% 44 (affected side)
and 19%  20 (unaffected side) in IG compared to -3%  21 (affected
side) and -2%  20 (unaffected side) in CG (between group comparison;
p¼0.0002). Isometric hip extension force increased 29%  35 (affected
side) and 26%  21 (unaffected side) in IG compared to -1%  16
(affected side) and 2%  18 (unaffected side) in CG (p<0.0001).
Isometric knee extension force increased 20%  27 (affected side) and
18%  21 (unaffected side) in IG compared to -4% 16 (affected side)
and -5% 16 (unaffected side) in group CG (p<0.0001). There were no
signiﬁcant differences between groups regarding baseline levels of age,
height, body weight, gender distribution or muscle function.
Conclusions: This randomized explorative trial showed that interven-
tion with 10 weeks of progressive preoperative RT induced a signiﬁcant
gain in muscle power and isometric muscle force compared with
controls in patients with end stage hip OA. This study holds promise to
provide information on the potential postoperative advantage on
outcome of progressive preoperative RT.280
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Purpose: A leading cause of knee osteoarthritis disability is pain. Non
steroidals, acetaminophen, and narcotics relieve pain but may have side
effects. Injectable hyanluronic acid (HA) may down regulate inﬂam-
matory and biochemical pain pathways. Bradykinin is a known neuro-
transmitter for pain. Our purpose was to compare placebo to oral HA.
The three hypotheses were: (1.) supplementation with oral HA would
signiﬁcantly improve knee pain and function over a 3 months period,
(2.) clinical response to oral HA would be related to metabolic
syndrome, and (3.) clinical response to oral HA would be related
changes in serum and synovial ﬂuid levels of bradykinin.
Methods: This was a prospective randomized double-blind placebo-
controlled study comparing a patented oral HA (Oralvisc) to placebo
for the treatment of knee OA. At completion two placebo patients
could not have arthrocentesis. All remaining data was available for 21
drug and 19 placebo patients. Subjects were between 50-75 years old,
had OA based on imaging, a visual analog score (VAS) >50 mm, and an
effusion where a joint aspiration or intra-articular injection would be
clinically indicated. Exclusion included recent trauma, any inﬂamma-
tory joint disorder, recent surgery, severe comorbidities, recent intra-
articular injections, and oral or topical corticosteroids. 576 patients
were screened and 51 recruited and randomized. 3 drug patients did
not return and 1 had surgery. 3 placebo patients did not return and 3
had enrollment errors. All patients took their preparation daily for 3
months. They were evaluated monthly for VAS and WOMAC pain and
joint function. Serum and synovial ﬂuid was collected at the beginning
and at 12 weeks. Bradykinin was measured by an ELISA. Patients were
assessed each month for any unused capsules receiving capsules for
the next four weeks. Initial body mass index (BMI), metabolic score
(MS) 0 - 4, MRI changes, Kellgren-Lawrence (KL) scores, age, race, and
sex were reviewed for the two groups. Repeated measures analyses
were used for all clinical comparisons including pain and function
scores as well as BMI. There were no restrictions on other pain
medications or therapies.
Results: Demographics, BMI, and KL scores were even for both groups.
The initial high VAS for placebo was 6.180.24cm and for drug was
6.750.28cm. After 3 months, the values fell to 5.840.76cm and
4.060.85cm respectively (p¼0.0035). The initial high WOMAC pain
score for placebo was 8.051.17 and for drug was 8.810.81. After 3
months the score rose to 8.161.13 for placebo and fell to 5.791.34 for
the drug group (p¼0.0259). The initial WOMAC function score was
40.535.18 for placebo and 40.293.07 for drug. After 3 months of
treatment, the score was reduced by 31% (27.627.44) for the drug
group but maintained for placebo (39.586.17), resulting in statistical
differences between treatment groups (p¼0.0132). The reduction in
VAS score (p¼0.0098) WOMAC pain (p¼0.0121) and WOMAC function
(p¼0.0169) was signiﬁcant for those taking HA but not for those taking
placebo (p < 0.05), showing signiﬁcant differences on the time
evolution of the studied parameters. The ﬁnal serum bradykinin levels
were signiﬁcantly lower for oral HA, 144 pg versus placebo 151 pg (p <0.05) with synovial ﬂuid decrease signiﬁcantly more for oral HA, 61 pg,
versus placebo -29 pg (p < 0.05). Change in bradykinin was inversely
related to MS.
Conclusions: Intra-articular HA may improve the symptoms of OA by
mitigating the activities of proinﬂammatory mediators and pain
producing neuropeptides released by activated synovial cells. Bradyki-
nins participate in innate immunity, inﬂammation, and pain. Chon-
drocyte receptors increase interleukin on stimulation. The relationship
of reduction of bradykinin and decreased pain in the oral HA group is
consistent with the role of bradykinin in joint pain. Further research
will be required to determine how this very promising agent leads to
changes in bradykinin levels.281
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Purpose: The Global Burden of Disease (GBD) was initially described in
the 1990s by the WHO as a “health gap”. This concept was particularly
useful for quantifying a population's health and determining public
health action priorities. Today the notion of a burden goes beyond the
idea of a “health gap”, and it is common to assess 2 types of burden for
chronic diseases: the global burden (assessment of the economic impact
of disease management for society as a whole and especially for the
payee) and the individual burden (handicap assessment, in the largest
sense of the term, as caused by the disease).
The goal was to develop a tool to measure the handicap of this chronic
condition on patients’ daily life in the largest sense of the term
(psychological, social, economic, and physical impact).
Methods: The questionnaire was developed in 3 phases: exploratory,
development, and validation (ﬁgure 1). A multidisciplinary team
(general practitioners, rheumatologists, patient associations, quality of
life experts) was involved throughout the entire rigorous methodolog-
ical process. These players, working in patient treatment or with
expertise in questionnaire development, made it possible to guarantee
the clinical and scientiﬁc applicability of the tool.
Results: Exploratory phase: An in-depth literature review concluded
that there are many different assessment tools used for osteoarthritis.
Some focus on a single joint (hip, knee, hand) or on pre/post prosthetics
attachment. Others were developed for very speciﬁc diseases (such as
rheumatoid arthritis) and do not concern osteoarthritis. The available
questionnaires do not cover certain ﬁelds such as the psychological and
aesthetic impacts of the disease, sufﬁciently or at all, even though the
latter is one of the primary causes of complaint.
In order to ensure the participation of patients with diverse proﬁles,
arthritic patients contributing to the question wording were recruited
by rheumatologists working privately or in hospitals, GP and patient
associations. In total, 130 subjects with osteoarthritis discussed their
complaints and handicaps related to osteoarthritis.
Following qualitative interviews, the main statements received were:
discouragement when dealing with the condition, difﬁculty completing
simple daily activities, changes in physical appearance, and the view of
arthritis as a handicap. Altered family interaction was emphasized over
altered interactionwith others. At this stage 56 items were organized to
generate 41 questions.
Development phase: Thewording of possible answers was set. An initial
assessment made it possible to limit redundancy by grouping similar
questions. Indiscriminate questions were also removed. The pilot
version of the questionnaire consisted of 25 questions, making it easier
to use in large-scale longitudinal studies.
Finally, a specialized institution used cognitive debrieﬁng to ensure
that each question was well-understood by and acceptable to
patients. This step did not bring about any major changes in question
wording.
Conclusions: This new questionnaire must undergo psychometric
validation before it can be used (for internal and external validity)*. A
factorial analysis would also be necessary to bring out the latent
characteristics measured by this questionnaire and identify the items
that are highly - or too closely - correlated between them. Finally,
a scoring system will be set to facilitate interpretation of the overall
handicap imposed by osteoarthritis on patients’ daily lives.
